// App-Quantinova.ai

: Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML

Researchers

Presenter

  • David T Yeung

Principal Investigators

  • John Reynolds

  • Susan Branford

  • Mannu Walia

  • Agnes S.M. Yong

  • Jake Shortt

  • Kate Burbury

  • Nicholas Viiala

  • Ilona Cunningham

  • David M. Ross

  • Rosemary Harrup

  • Matthew Wright

  • Cecily Forsyth

  • Alwyn Bernard D'Souza

  • Robin J Filshie

  • Peter J. Browett

  • Steven W Lane

  • Carolyn Grove

  • Andrew Grigg

  • Timothy Hughes

Medical Centers

  • Auckland City Hospital, Grafton, New Zealand

  • Capital Coast Health and Otago University, Wellington, New Zealand

  • Gosford Hospital and Newcastle University, Gosford, Australia

  • Haematology Department, Concord Repatriation General Hospital, University of Sydney, Sydney, Australia

  • South Australian Health and Medical Research Institute SAHMRI, Adelaide, Australia

  • Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia

  • Haematology, Royal Perth Hospital and University of Western Australia, Perth, Australia

  • School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

  • Department of Haematology, Sir Charles Gairdner Hospital & PathWest, Nedlands, Australia

  • Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia

  • Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia

  • Peter MacCallum Cancer Centre, MELBOURNE, Australia

  • Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia

  • Department of Clinical Haematology, Austin Health, Heidelberg, Australia

  • Cancer Program, Queensland Institute of Medical Research, Brisbane, Australia

  • Australasian Leukaemia and Lymphoma Group, Richmond, Australia

  • Haematology, Flinders Medical Centre and Flinders University, Bedford Park, Australia

  • Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia

  • The Alfred Hospital and Monash University, Melbourne, Australia

  • Monash Haematology, Monash Health, Clayton, Australia

  • University of NSW, Sydney, Australia

  • Liverpool Hospital, Sydney, Australia

  • Department of Haematology, Fiona Stanley Hospital, Perth, Australia

  • School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia

  • Department of Molecular Medicine and Pathology, University of Auckland School of Medicine, Auckland, New Zealand

  • Royal Hobart Hospital, University of Tasmania, Tasmania, Australia

  • Adelaide Medical School, The University of Adelaide, Adelaide, Australia

  • Department of Hematology, St. Vincent's Hospital Melbourne, Melbourne, Australia

Locations

  • New Zealand

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Thrombocytopenia

  • Pancreatitis

  • Neutropenia

  • Lymphomas

Biomarkers

  • Aspartate aminotransferase

  • Alanine transaminase

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Cluster of Differentiation 206

Drug/Treatment

  • Nilotinib

  • dasatinib

  • ABL001

  • Imatinib

  • IkT001

  • lipase

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Open Label

  • Tolerability

  • Prospective

  • Dose Escalation

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved